Canaccord Genuity Starts Aduro Biotech (ADRO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
BofA/Merrill Lynch Starts Aduro Biotech (ADRO) at Buy
May 11, 2015 7:23 AM EDTBofA/Merrill Lynch initiated coverage on Aduro Biotech (NASDAQ: ADRO) with a Buy rating.
For an analyst ratings summary and ratings history on Aduro Biotech click here. For more ratings news on Aduro Biotech click here.
Shares of Aduro Biotech closed at $30.85 yesterday.
... MoreWilliam Blair Starts Aduro Biotech (ADRO) at Outperform
May 11, 2015 7:20 AM EDTWilliam Blair initiated coverage on Aduro Biotech (NASDAQ: ADRO) with an Outperform rating.
For an analyst ratings summary and ratings history on Aduro Biotech click here. For more ratings news on Aduro Biotech click here.
Shares of Aduro Biotech closed at $30.85 yesterday.
... MoreLeerink Partners Starts Aduro Biotech (ADRO) at Outperform
May 11, 2015 6:29 AM EDTLeerink Partners initiates coverage on Aduro Biotech (NASDAQ: ADRO) with a Outperform rating and a price target of $48.00.
Analyst Howard Liang commented, "We are initiating coverage of Aduro BioTech (ADRO) with an Outperform rating and price target of $48/share. ADRO is a clinical-stage... More
